Inhibitory effect of a long-acting somatostatin analogue on EGF-stimulated cell proliferation in Capan-2 cells

B Burghardt1, K Barabás, Z Marcsek

  • 1Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest.

Insights

Epidermal growth factor (EGF) stimulates pancreatic cancer cell growth, while somatostatin (octreotide) inhibits it. Cholecystokinin (CCK) did not affect proliferation in Capan-2 cells, which lack CCK receptors.

Area of Science:

  • Gastroenterology
  • Oncology
  • Molecular Biology

Background:

  • Gut-derived peptides have controversial effects on pancreatic cancer growth.
  • Epidermal growth factor (EGF) is known to stimulate pancreatic cell proliferation.
  • The roles of somatostatin and cholecystokinin (CCK) in pancreatic cancer cell proliferation are unclear.

Purpose of the Study:

  • To investigate the expression of CCK-A, CCK-B, and somatostatin-2 (SSTR2) receptors in human pancreatic adenocarcinoma Capan-2 cells.
  • To determine the effects of EGF, CCK, and octreotide (a somatostatin analogue) on DNA synthesis in Capan-2 cells.

Main Methods:

  • Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect receptor mRNA expression.
  • Capan-2 cells were cultured and treated with EGF, CCK, or octreotide.
  • [3H]-thymidine incorporation was measured to assess DNA synthesis.

Main Results:

  • Capan-2 cells expressed SSTR2 mRNA but not CCK-A or CCK-B receptor mRNA.
  • EGF significantly increased DNA synthesis by 45.2%, while octreotide decreased it by 11.7%.
  • Combined EGF and octreotide treatment resulted in a lower increase in DNA synthesis compared to EGF alone. CCK did not significantly affect DNA synthesis.

Conclusions:

  • EGF acts as a growth factor for the Capan-2 human pancreatic cancer cell line.
  • Somatostatin (via octreotide) plays a regulatory role in Capan-2 cell proliferation.
  • CCK does not appear to affect proliferation in this pancreatic cancer cell line due to a lack of CCK receptors.